"Those with the highest burden of comorbidity had over a 30% increased risk of having disability worsening," Salter said. "In ...

For people with multiple sclerosis (MS), a higher burden of comorbidity is associated with worse clinical outcomes, according ...

The revisions signal a shift toward looking at MS more as a biologically based disease, noted Xavier Montalban, MD, PhD, of ...

AB SCIENCE PROVIDES AN UPDATE ON THE DEVELOPMENT OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS POST ECTRIMS 2024 Paris, 23 September 2024, 5.45pm CET AB Science SA (Euronext - FR0010557264 - ...

The totality of data from Sanofi clinical trials indicates that Tolebrutinib may target inflammation thought to contribute to ...

Columnist Desiree Lama has accepted her MS diagnosis as part of her identity — but it's not the only thing that defines her, ...

A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...

Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...

Ms Corner said it shows "the part of John’s story that is rarely seen beyond his closest family" as he lies pensive in bed.

Gaps in access to care persist for US patients with MS and impact HRQOL to a large extent. Improving access to care for patients with MS should be prioritized.

Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous ...

Patients with MS showed half the rate of amyloid pathology compared with people without MS, suggesting a possible protective ...